


## Data Sheet

[WWW.UREIKO-CHEM.COM](http://WWW.UREIKO-CHEM.COM)

Global Supplier of Chemical Probes, Inhibitors & Agonists

<b>Product Name</b>	:PT2385
<b>Cat.No.</b>	:URK-V622
<b>CAS No.</b>	:1672665-49-4
<b>Molecular Formula</b>	:C <sub>17</sub> H <sub>12</sub> F <sub>3</sub> NO <sub>4</sub> S
<b>Molecular Weight</b>	:383.342
<b>Target</b>	:HIF/HIF Prolyl-hydroxylase
<b>Solubility</b>	:10 mM in DMSO



### Biological Activity

PT2385 (PT-2385) is a potent, selective, and orally active antagonist of HIF2 $\alpha$ , binds to HIF2 $\alpha$  PAS-B domain (K<sub>d</sub>=50 nM) and disrupts HIF2 $\alpha$ /ARNT dimer formation; allosterically blocks HIF2 $\alpha$  dimerization with the HIF1 $\alpha$ /2 $\alpha$  transcriptional dimerization partner ARNT/HIF1 $\beta$ , disrupts HIF2 $\alpha$ , but not HIF1 $\alpha$ , heterodimerization with ARNT in Hep3B cells; inhibits the expression of HIF2 $\alpha$ -dependent genes, including VEGF-A, PAI-1, and cyclin D1 in ccRCC cell lines and tumor xenografts, also reduces HIF2 $\alpha$  mRNA and protein levels in xenograft tumors.

Kidney Cancer  
Phase 2 Clinical

### References

1. Wallace EM, et al. Cancer Res. 2016 Sep 15;76(18):5491-500.
2. Chen W, et al. Nature. 2016 Nov 3;539(7627):112-117.
3. Courtney KD, et al. J Clin Oncol. 2018 Mar 20;36(9):867-874.
4. Xie C, et al. Nat Med. 2017 Nov;23(11):1298-1308.

*Note: All products of Ureiko are only used for scientific research or drug certificate declaration, we do not provide products and services for any personal use!*

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

[JACK@UREIKO-CHEM.COM](mailto:JACK@UREIKO-CHEM.COM)